Braveheart Bio (NASDAQ:BRVE) Stock Keeps Overweight Rating at Cantor Fitzgerald

Braveheart Bio (NASDAQ:BRVE)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $40.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 104.00% from the company’s previous close.

A number of other equities analysts have also weighed in on BRVE. Jefferies Financial Group began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 target price for the company. The Goldman Sachs Group began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 price objective for the company. Stifel Nicolaus began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 price objective for the company. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. Finally, TD Cowen assumed coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Braveheart Bio Stock Performance

Shares of BRVE traded up $0.40 during mid-day trading on Tuesday, reaching $19.61. The stock had a trading volume of 23,189 shares, compared to its average volume of 459,142. The firm has a market capitalization of $1.77 billion and a price-to-earnings ratio of -7.82. Braveheart Bio has a 12 month low of $17.86 and a 12 month high of $32.00. The business’s fifty day moving average price is $24.50.

Braveheart Bio (NASDAQ:BRVE) last posted its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). As a group, equities analysts anticipate that Braveheart Bio will post -1.48 earnings per share for the current fiscal year.

Insider Transactions at Braveheart Bio

In other news, Director Erez Chimovits bought 1,940,000 shares of the stock in a transaction dated Friday, August 7th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the acquisition, the director owned 11,901,826 shares of the company’s stock, valued at $214,232,868. The trade was a 19.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bio Fund Iv L.P. Ah bought 1,100,000 shares of the stock in a transaction dated Friday, August 7th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider directly owned 10,232,420 shares in the company, valued at approximately $184,183,560. The trade was a 12.05% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 8,751,942 shares of company stock worth $157,534,956.

Braveheart Bio Company Profile

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.